Treatment options for children with multi-drug resistant tuberculosis
G Bossù, G Autore, L Bernardi… - Expert Review of …, 2023 - Taylor & Francis
Introduction According to the latest report from the World Health Organization (WHO),
approximately 10.0 million people fell ill with tuberculosis (TB) in 2020, 12% of which were …
approximately 10.0 million people fell ill with tuberculosis (TB) in 2020, 12% of which were …
At long last: short, all-oral regimens for multidrug-resistant tuberculosis in the United States
Multidrug-resistant tuberculosis (MDR-TB) has historically required longer treatment
regimens that were associated with higher unfavorable outcomes and side effects rates …
regimens that were associated with higher unfavorable outcomes and side effects rates …
[HTML][HTML] The socio-demographic, clinical characteristics and outcomes of tuberculosis among HIV infected adults in Lithuania: A thirteen-year analysis
E Matulyte, E Davidaviciene, Z Kancauskiene… - Plos one, 2023 - journals.plos.org
Background Tuberculosis (TB) is a public health problem in Lithuania, among the 18 high-
priority TB countries in the European region, and the most common AIDS-indicative disease …
priority TB countries in the European region, and the most common AIDS-indicative disease …
[HTML][HTML] Treatment outcomes of multidrug-resistant tuberculosis patients receiving ambulatory treatment in Shenzhen, China: a retrospective cohort study
J Lecai, P Mijiti, H Chuangyue, G Qian… - Frontiers in Public …, 2023 - frontiersin.org
Background WHO recommended multidrug-resistant tuberculosis (MDR-TB) should be
treated mainly under ambulatory model, but outcome of ambulatory treatment of MDR-TB in …
treated mainly under ambulatory model, but outcome of ambulatory treatment of MDR-TB in …
[HTML][HTML] Coping with drug resistant tuberculosis alongside COVID-19 and other stressors in Zimbabwe: a qualitative study
C Timire, K Kranzer, D Pedrazzoli… - PLOS Global Public …, 2023 - journals.plos.org
Households in low-resource settings are more vulnerable to events which adversely affect
their livelihoods, including shocks eg death of family members, droughts and more recently …
their livelihoods, including shocks eg death of family members, droughts and more recently …
[HTML][HTML] Advances in computational frameworks in the fight against TB: The way forward
Around 1.6 million people lost their life to Tuberculosis in 2021 according to WHO estimates.
Although an intensive treatment plan exists against the causal agent, Mycobacterium …
Although an intensive treatment plan exists against the causal agent, Mycobacterium …
[HTML][HTML] Evaluation of genetic mutations associated with phenotypic resistance to Fluoroquinolones, Bedaquiline, and Linezolid in clinical Mycobacterium tuberculosis …
Q An, R Lin, Q Yang, C Wang, D Wang - Journal of Global Antimicrobial …, 2023 - Elsevier
Objectives The classification of drugs used in multidrug-resistant tuberculosis (MDR-TB)
regimens was updated. Group A drugs (fluoroquinolones, bedaquiline (BDQ), and linezolid …
regimens was updated. Group A drugs (fluoroquinolones, bedaquiline (BDQ), and linezolid …
[HTML][HTML] Time to treatment and risk factors for unsuccessful treatment outcomes among people who started second-line treatment for rifampicin-resistant or multi-drug …
B Kyrbashov, A Kulzhabaeva, A Kadyrov… - Tropical Medicine and …, 2023 - mdpi.com
The Kyrgyz Republic is a high-burden country for rifampicin resistant/multi-drug resistant
tuberculosis (RR/MDR-TB). TB control efforts rely on early diagnosis and initiation of people …
tuberculosis (RR/MDR-TB). TB control efforts rely on early diagnosis and initiation of people …
[HTML][HTML] Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed
after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb …
after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb …
[HTML][HTML] Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment
Objective Studying treatment duration for rifampicin-resistant and multidrug-resistant
tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We …
tuberculosis (MDR/RR-TB) using observational data is methodologically challenging. We …